Springer Nature

Data from AbbVie and Johnson & Johnson will fine-tune OpenFold3 in a confidentiality-preserving environment, powered by Apheris.

Beyond speed, AI has also helped reduce costs. Conventional methods required nearly $35,000 per genome analysis, but AI-driven models running on GPUs have lowered the cost to under $2,000, making high-quality genomic research more accessible.

The National Synchrotron Light Source II (NSLS-II)—a U.S. Department of Energy (DOE) Office of Science user facility at DOE's Brookhaven National Laboratory—is among the world's most advanced synchrotron light sources,

Telescope Innovations Corp. (CSE:TELI) is leveraging its expertise to advance chemistry process development and crystallization optimization in pharmaceuticals, industrial chemicals, and critical minerals ・Telescope's Self-Driving Labs (SDLs) integrate AI,

Proteins play a crucial role in nearly all biological processes, yet predicting their complex interactions and designing proteins with new functions poses a significant challenge. In a new study published in Nature (DOI: 10.

Bioptimus, the pioneering AI foundation model company, announced today that it has reached a significant funding milestone of $76 million. This total includes a $41 million cash injection, led by Cathay Innovation with participation from prominent investors,

Absci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications,

QIAGEN is continuously integrating AI technology in its QDI portfolio. In early 2024, QIAGEN released an AI-driven biomedical knowledgebase to drive data-driven drug discovery and in late 2023, QIAGEN released an AI-driven enhancement to its market-leading QIAGEN Clinical Insight Interpret product capabilities.